Niv Papo

About Niv Papo

Angiogenesis is the process of new blood vessel development, a hallmark of cancer and Prostate Specific Membrane Antigen (PSMA) is a protein expressed on the surface of prostate tumor cells.
Dr. Papo intends to produce engineered proteins that will simultaneously bind to PSMA on prostate cancer cells and inhibit angiogenesis.
This engineered protein inhibitor should be a drug candidate for the treatment advanced, metastatic prostate cancer.
What this means for patients: This is a novel therapeutic candidate for the treatment of advanced, metastatic prostate cancer.

Award

2013 Joseph Neubauer-PCF Young Investigator

Niv Papo, PhD

Ben-Gurion University of the Negev (Israel)

Mentor:

Eyal Mishani, PhD

Project Title:

Developing novel dual-specific proteins that target multiple receptors for applications in prostate cancer imaging and therapy